Evoke Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVOK research report →
Range $18 – $18
Price Chart
About the company
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials.
- CEO
- Mark A. Kowieski
- IPO
- 2013
- Employees
- 3
- HQ
- Solana Beach, CA, US
Get TickerSpark's AI analysis on EVOK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.95M
- P/E
- -10.28
- Fwd P/E
- 16.18
- PEG
- -0.06
- P/S
- 2.36
- P/B
- 8.37
- EV/EBITDA
- -5.04
- Div Yield
- 0.00%
- Gross Margin
- 96.64%
- Op Margin
- -33.56%
- Net Margin
- -33.94%
- ROE
- -70.50%
- ROIC
- -31.82%
Latest fiscal year · YoY change
- Revenue
- $10.25M+97.8%
- Gross Profit
- $9.89M+98.7%
- Op Income
- $-5,204,137
- Net Income
- $-5,352,194+31.3%
- EPS
- $-2.81+90.0%
- OCF Growth
- -9.5%
- FCF Growth
- -9.5%
- 52W High
- $11.00
- 52W Low
- $1.94
- 50D MA
- $8.52
- 200D MA
- $5.04
- Beta
- -0.14
- RSI (14)
- 85
- Avg Volume
- 100.37K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Evoke Pharma reported strong 2024 sales growth driven by better fulfillment and provider adoption, and guided 2025 revenue to about $16 million while extending cash runway into Q1 2026.· March 13, 2025
- Full-year 2024 net product sales were approximately $10.2 million, up from approximately $5.2 million in 2023.
- Fourth-quarter 2024 net product sales were approximately $3.3 million versus $1.7 million a year ago.
- Management said the Aspen pharmacy transition, broader pharmacy network, and improved commercialization drove faster fulfillment, higher fill rates, and more prescribers.
- 2025 net revenue guidance is approximately $16 million, or about 60% growth versus 2024.
- Cash and cash equivalents were approximately $13.6 million at year-end, and management said this funds operations into the first quarter of 2026.
For the fourth quarter of 2024, net product sales were approximately $3.3 million versus $1.7 million in the fourth quarter of 2023; net loss was approximately $1.2 million, or $0.49 per share, versus $2.0 million, or $7.13 per share. For full-year 2024, net product sales were approximately $10.2 million versus approximately $5.2 million in 2023; net loss was approximately $5.4 million, or $2.81 per share, versus $7.8 million, or $27.97 per share. SG&A was approximately $4.4 million in Q4 and approximately $15.1 million for the full year, while R&D was negligible at $0 in Q4 and approximately $16,000 for the year. Cash and cash equivalents were approximately $13.6 million at December 31, 2024, and management said existing cash plus future Gimoti sales should fund operations into the first quarter of 2026. The company projected 2025 net revenue of approximately $16 million, which it said represents about 60% growth over 2024.
Matthew D’Onofrio framed the quarter as evidence that Evoke is “scratching the surface” in a large underpenetrated market. He emphasized the commercial strategy: expanding pharmacy partnerships, improving access and prior authorization support, building provider awareness, and using real-world data to support Gimoti as a standard-of-care option. His tone was confident and mission-driven, reinforced by a patient story showing reduced ER use and weight recovery after starting Gimoti.
Mark Kozlowski focused on the financial lift from commercialization and fulfillment improvements. He cited Q4 net product sales of approximately $3.3 million, full-year sales of approximately $10.2 million, and the year-end cash balance of approximately $13.6 million, saying the company’s financing and sales trajectory support runway into Q1 2026. He also pointed to higher SG&A from marketing, advertising, and profit-sharing costs, and said SG&A should increase further as commercialization expands and Eversana reimbursement continues.
An analyst asked about the competitive impact of Vanda’s CRL and the FDA’s notice that compassionate-use Domperidone will be discontinued. Management said the exact volume of affected patients is unknown, but believes another option going away later this year reinforces Gimoti’s role and could ultimately push patients toward Gimoti. The analyst also asked about Medicaid and Medicaid-like pharmacy access; management said adding seven dispensing pharmacies helped, and Medicaid scripts have grown from about 2% of business early in 2024 to roughly 5% to 7% depending on the month.
Management believes multiple growth levers remain: more prescribers, deeper prescribing per doctor, faster time to therapy, and higher conversion rates from added pharmacies and FRM support. They also see external validation from real-world data and from changes in the competitive landscape, which they think strengthen Gimoti’s value proposition and market leadership.
The company still faces access and execution risks, including prior authorizations that are only being completed about 50% of the time and dependence on pharmacy network coverage to reduce abandonment and leakage. Management also acknowledged external uncertainties in guidance, including macro conditions, supply chain constraints, and inflation, while saying the Domperidone opportunity is hard to quantify because the patient count is unknown.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.3%
- Shares Outstanding
- 1.72M
- Float Shares
- 1.40M
of shares held by institutions
23 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Fund Advisors | 31.13K | ▲ 4.43K |
| Commonwealth Equity Services, Inc | 30.06K | 0 |
| Blackrock Investment Management, LLC | 1.28K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 148,153 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 433,962 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 117,019 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 117,019 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 158,531 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 250,627 |
| Dec 17, 25 | PYSZCZYMUKA GREG | sell | 5,833 |
| Dec 17, 25 | PYSZCZYMUKA GREG | sell | 1,155 |
| Dec 17, 25 | Smeal Benjamin C. | sell | 5,833 |
| Dec 17, 25 | Smeal Benjamin C. | sell | 1,125 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVOK coverage
Recent articles, reports, and earnings notes.
No research on EVOK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVOK report →Evoke revenue falls 7% to £406m as shop closures and customer-friendly results weigh
proactiveinvestors.com · Oct 23
Evoke H1 Earnings Call Highlights
marketbeat.com · Aug 12
Evoke shares jump 16% as William Hill owner agrees £243m takeover by Bally's Intralot
proactiveinvestors.co.uk · Jun 5
Evoke Agrees to $326 Million Takeover Bid From Bally's Intralot
wsj.com · Jun 5
William Hill UK owner Evoke agrees $326 million takeover by Bally's Intralot
reuters.com · Jun 5
William Hill owner Evoke in talks with Ball's Intralot about potential takeover
proactiveinvestors.co.uk · Apr 20
William Hill UK owner Evoke confirms $304 million takeover bid from Bally's Intralot
reuters.com · Apr 20
William Hill owner Evoke reports strongest quarter of the year, sale process ongoing
proactiveinvestors.co.uk · Jan 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.